Skip to main content
Clinical Trials/IRCT20200509047364N3
IRCT20200509047364N3
Not yet recruiting
Phase 3

Evaluation of the efficacy of N-Acetylcysteine in severe COVID-19 patients: a randomized controlled phase III clinical trial

Bandare-abbas University of Medical Sciences0 sites40 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Bandare-abbas University of Medical Sciences
Enrollment
40
Status
Not yet recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Bandare-abbas University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • All COVID\-19 patients whose disease has been confirmed by the PCR test for SARS\-Cov\-2\.
  • Having one of the criteria for severe COVID\-19 disease includes tachypnea (respiration rate\> 30 per minute), hypoxemia (O2 \= saturation, arterial oxygen partial pressure ratio \<300\), pulmonary infiltration (\> 50% of lung area during 24 48 h), LDH\> 245 U / l, Progressive lymphopenia.
  • Hospitalized in the intensive care unit.
  • Signing the written consent of the study participant.

Exclusion Criteria

  • Known allergy or hypersensitivity to N\-Acetylcysteine.
  • The participant refused to participate in the continuation of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials